Fivephusion

FivepHusion is a globally focused, advanced clinical stage, biotech company driven to optimize chemotherapy to improve patient treatment outcomes and quality of life. Throughout our lives, each of us will either experience the trauma of cancer first-hand, or through the experiences of a family member or friend. Unfortunately, standard chemotherapy used to treat cancer often has limited therapeutic benefit, with a significant side effect burden and serious impact on quality of life. We are developing Deflexifol™ as a replacement of sub-optimal standard of care chemotherapy for the treatment of metastatic colorectal cancer, and other tumors with a projected global incidence of greater than 6 million patients. Deflexifol™ is also being developed as a new therapy for cancers with high unmet medical need, such as pediatric ependymoma; a rare and deadly brain cancer which afflicts very young children.